No OS Improvement with CDK4/6 Inhibitors Used in First- Compared with Second-Line Treatment in Patients with HR-positive, HER2-negative ABC By Ogkologos - March 3, 2026 119 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the SONIA study Source RELATED ARTICLESMORE FROM AUTHOR Low-Dose Pembrolizumab with Dose-Dense Chemotherapy Increases pCR as Neoadjuvant Treatment for Localised TNBC ESMO Advocates for Equal Access to Optimal Cancer Care for all Patients with Cancer at the 79th World Health Assembly Daraxonrasib Shows Antitumour Activity Among Patients with Previously Treated RAS-mutated Pancreatic Ductal Adenocarcinoma MOST POPULAR ALK Mutations and Amplifications are Independent Predictors of Poorer Survival in... June 24, 2021 The Doctor Will See You Now…On the Screen July 2, 2020 Intercontinental Asian Study Compiles the Relative Incidence of non-Hodgkin T-cell Lymphoma... November 21, 2020 如果您剛確診為肺癌患者，請來看看專家的回答 April 22, 2021 Load more HOT NEWS 6 Things to Know About Regrowing and Caring for Your Hair... EMA Recommends Granting a Marketing Authorisation for Elacestrant Heartburn Medications Pulled From Shelves Because They May Cause Cancer Scientists uncover how incurable skin cancer resists treatment at the end...
